Vineet Laboratories Limited (VINEETLAB) Share Price

NSE · Basic Materials · Chemicals · ISIN INE505Y01010

₹37.70+0.20 (+0.53%)

Key metrics

Market Cap
₹73 Cr
P/E Ratio
65.45
EPS
-7.5
Book Value
23.74
P/B Ratio
1.6
ROE
2.44%
ROCE
6.67%
Debt / Equity
0.99
Net Margin
1.87%
Revenue Growth
-20.79%
Profit Growth
105.5%
Dividend Yield
52W High
₹49.99
52W Low
₹27.96
Market Cap Band
micro cap
Face Value

Ratios computed from the annual results period ending 2026-03-31.

About Vineet Laboratories Limited

Vineet Laboratories Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API), intermediates, and fine chemicals primarily in India. The company offers intermediates of Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, Piroctone Olanine, and other API intermediates. It also provides fine chemicals and reagents, such as isopropyl-beta-d-thiogalactopyranoside, n-butyl lithium, 4-nitrophenyl phosphate disodium salt, 5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside, 5-acetyl thiophene-2-carboxilic acid, 4-chlorobutyryl chloride, n-butyl magnesium chloride, 3-furaldehyde, 3-bromofuran, n-butylnitrite, ethyldiazo acetate, phenylboronic acid, 6-aminouracil, and 1-methyl-imidazole-2-carboxaldehyde. The company was incorporated in 2016 and is based in Hyderabad, India.

Headquarters
Hyderabad, India
Promoter Holding
37.34%

The full Vineet Laboratories Limited analysis

Create a free account to open the complete VINEETLAB deep-dive — fourteen tabs of fundamental, technical, institutional and ownership data.

  • 10-year financialsIncome statement, balance sheet and cash flow, year by year.
  • Valuation & fair valueFair-value estimates, quality scores and a value grade.
  • Charts & technicalsCandlestick charts, RSI, MACD, Supertrend and detected patterns.
  • Shareholding historyPromoter, FII, DII and public holdings across every quarter.
  • Ace investor holdingsWhich well-known investors hold it, and how their stake changed.
  • Deals & insider tradesBulk and block deals, insider transactions and mutual-fund holdings.